Enveric Biosciences Inc./$ENVB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Ticker
$ENVB
Sector
Primary listing
Employees
6
Headquarters
Website
ENVB Metrics
BasicAdvanced
$4M
-
-$7.08
0.37
-
Price and volume
Market cap
$4M
Beta
0.37
52-week high
$3.10
52-week low
$1.01
Average daily volume
149K
Financial strength
Current ratio
2.425
Quick ratio
2.09
Total debt to equity
4.571
Interest coverage (TTM)
-17,418.88%
Profitability
EBITDA (TTM)
-9.675
Effective tax rate (TTM)
-0.07%
Management effectiveness
Return on assets (TTM)
-129.73%
Return on equity (TTM)
-261.96%
Valuation
Price to book
1.69
Price to tangible book (TTM)
1.69
Price to free cash flow (TTM)
-0.263
Free cash flow yield (TTM)
-380.33%
Free cash flow per share (TTM)
-4.64
Growth
Earnings per share change (TTM)
-82.15%
3-year earnings per share growth (CAGR)
-81.06%
ENVB News
AllArticlesVideos
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Business Wire·1 month ago
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
Business Wire·1 month ago
Enveric Biosciences Announces Participation in 2025 BIO International Convention
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enveric Biosciences Inc. stock?
Enveric Biosciences Inc. (ENVB) has a market cap of $4M as of August 23, 2025.
What is the P/E ratio for Enveric Biosciences Inc. stock?
The price to earnings (P/E) ratio for Enveric Biosciences Inc. (ENVB) stock is 0 as of August 23, 2025.
Does Enveric Biosciences Inc. stock pay dividends?
No, Enveric Biosciences Inc. (ENVB) stock does not pay dividends to its shareholders as of August 23, 2025.
When is the next Enveric Biosciences Inc. dividend payment date?
Enveric Biosciences Inc. (ENVB) stock does not pay dividends to its shareholders.
What is the beta indicator for Enveric Biosciences Inc.?
Enveric Biosciences Inc. (ENVB) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.